Relapse Escalation treatment trial in Optic Neuritis (RESCON):
Relapse Escalation treatment trial in Optic Neuritis (RESCON):
What it found
The trial ended early for another reason (see below).
This trial finished 11 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Compared with
- Methylprednisolone
Glucocorticoid receptor agonist
What it measured
Main measures
Difference of Mean RNFL thickness in both groups at week 16
Retina scans (OCT)Mean retina nerve fiber layer thickness in OCT at week 16 after treatment in comparison between groups
Retina scans (OCT)
Other measures (2)
Treatment failure at week 2,
1. Treatment failure at week 2 2. Visual acuity measured at inclusion, week 2, 4, 8, 16, 52 after treatment 3. Visual evoked potential latency measured at inclusion, week 2, 4, 8, 16, 52 after treatment 4. MRI parameters at week 1, 2, 4, 16, 52
MRI lesionsMyelin repairVision
Who could take part
Relapsing and progressive · 18 to 60
Show the full criteria
Inclusion criteria
Inclusion: o Optic neuritis with visual acuity < 0.7 after steroid treatment (3-5x1g) Exclusion: o absence of evidence of inflammatory activity which is defined as a lack of inflammatory CSF signs (pleocytosis and/or OCBs) or a present MRI without at least 2 MS-typical lesions
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
- to gain further evidence for the efficacy of plasma exchange in steroid-unresponsive optic neuritis
Loading reviews and guidelines…
History
Started
Oct 2012
Finished
Oct 2015